NCT02884180 (DEXRAR) is a Phase 4 clinical trial of Dexamethasone in Pain, Postoperative, sponsored by Daniel Hägi-Pedersen.

Who is sponsoring NCT02884180?

NCT02884180 is sponsored by Daniel Hägi-Pedersen.

What drugs are being tested in NCT02884180?

Interventions in NCT02884180: Dexamethasone, Saline isotonic.

What condition does NCT02884180 study?

NCT02884180 studies Pain, Postoperative.

Is NCT02884180 still recruiting?

NCT02884180 is currently terminated. Last updated 23 May 2025.

Last reviewed 2025-05-23 · How we verify

NCT02884180: DEXRAR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DEXRAR: DEXamethasone in Revision ARthroplasty

Terminated Phase 4 Last updated 23 May 2025

What this trial tests

Phase 4 trial testing Dexamethasone in Pain, Postoperative in 98 participants. Terminated before completion.

Timeline

31 May 2017

Primary endpoint
31 December 2024

31 March 2025

Quick facts

Lead sponsor	Daniel Hägi-Pedersen
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	98
Start date	31 May 2017
Primary completion	31 December 2024
Estimated completion	31 March 2025
Sites	1 location across Denmark

Drugs / interventions tested

Dexamethasone (dexamethasone) — full drug profile →
Saline isotonic — full drug profile →

Conditions studied

Pain, Postoperative — all drugs for Pain, Postoperative →

Sponsor

Daniel Hägi-Pedersen — full company profile →

Who can join

18 and older, any sex, with Pain, Postoperative. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Trial name: DEXRAR: Dexamethasone in revision arthroplasty: A randomised, blinded, 2-group clinical trial Trial acronym: DEXRAR Background: Effective postoperative pain management is essential for the well-being and rehabilitation of the surgical patient. No "gold standard" exists for pain treatment after revision total knee arthroplasty (TKA) and combinations of different medications are used with virtually no evidence for combined analgesic efficacy. Objectives: The objective is to investigate the analgesic effect and safety of dexamethasone as a single dose after revision-TKA in combination with paracetamol, ibuprofen and local infiltration analgesia Intervention: The patients are randomised into to groups: A) 24 mg dexamethasone i.v. B) isotonic saline i.v. Design and trial size: Placebo controlled, parallel 2-group trial with adequate centralised computer-generated allocation sequence and allocation concealment with block size of 12. Blinding of assessor, investigator, caregivers and patients. Sample size: 108 eligible patients are needed to detect a difference of 11,3 mg morphine for the first 24 h postoperatively with a standard deviation of 20 mg, a type 1 error rate of 0,05 and a type 2 error rate of 0,20.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S, Rücker G, Eberhart LH, Pace NL, et al · · 2020 · cited 125× · PMID 33075160 · DOI 10.1002/14651858.cd012859.pub2

Verify or expand the search:

Other trials of Dexamethasone

Trials testing the same drug.

NCT07543458 — Therapeutics for Moderate and Severe Dengue · Phase 3 · not yet recruiting
NCT07175415 — HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological · Phase 1, PHASE2 · not yet recruiting
NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Pain, Postoperative

Currently open trials in the same condition.

NCT07512141 — Single Versus Double Drains in the Axillary and Pectoral Regions After Modified Radical Mastectomy · NA · recruiting
NCT07354581 — Erector Spinae Plane Block vs Quadro-Iliac Plane Block After Lumbar Instrumentation Surgery · NA · recruiting
NCT07239817 — PENG Block + LIA For Endoprosthesis Surgery With Anterior Approach · NA · recruiting
NCT06740214 — Analgesic Efficacy of Different Liposomal Bupivacaine Doses in the Adductor Canal Block for Total Knee Arthroplasty · Phase 3 · recruiting
NCT07057557 — Aloe Vera vs Paraffin Tulle Dressings for Pain Management in Split Thickness Skin Graft Donor Sites · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02884180 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daniel Hägi-Pedersen
Last refreshed: 23 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02884180.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing